Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 129
Filter
2.
Case Rep Crit Care ; 2019: 1598213, 2019.
Article in English | MEDLINE | ID: mdl-31934457

ABSTRACT

BACKGROUND: Multiple acyl-coA dehydrogenase deficiency (MADD) is a rare, inherited, autosomal-recessive disorder leading to the accumulation of acylcarnitine of all chain lengths. Acute decompensation with cardiac, respiratory or hepatic failure and metabolic abnormalities may be life-threatening. CASE PRESENTATION: A 29-year-old woman presented with severe lactic acidosis associated with intense myalgia and muscle weakness. The clinical examination revealed symmetric upper and lower limb motor impairment (rated at 2 or 3 out of 5 on the Medical Research Council scale) and clear amyotrophy. Laboratory tests had revealed severe rhabdomyolysis, with a serum creatine phosphokinase level of 8,700 IU/L and asymptomatic hypoglycemia in the absence of ketosis. Electromyography revealed myotonic bursts in all four limbs. The absence of myositis-specific autoantibodies ruled out a diagnosis of autoimmune myositis. Finally, Acylcarnitine profile and gas chromatography-mass spectrometry analysis of organic acids led to the diagnosis of MADD. A treatment based on the intravenous infusion of glucose solutes, administration of riboflavin, and supplementation with coenzyme Q10 and carnitine was effective. Lipid consumption was strictly prohibited in the early stages of treatment. The clinical and biochemical parameters rapidly improved and we noticed a complete disappearance of the motor deficit, without sequelae. CONCLUSION: A diagnosis of MADD must be considered whenever acute or chronic muscle involvement is associated with metabolic disorders. Acute heart, respiratory or hepatic failure and metabolic abnormalities caused by MADD may be life-threatening, and will require intensive care.

3.
Neurochirurgie ; 64(6): 439-441, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30274919

ABSTRACT

Erdheim-Chester disease is a rare form of non-Langerhans cell histiocytosis. It is an inflammatory disorder associated with BRAF V600E mutation in 50% of cases. This multisystem disease is rarely associated with spinal involvement. Neurological involvement is an independent predictive factor of poor prognosis. The diagnosis is histopathological based on CD68-positive and CD1A-negative histiocytes. Treatment with interferon-alpha is an independent predictor of survival in Erdheim-Chester disease and vemurafenib has also been shown to be effective for BRAF V600E mutation. We report a clinical case of a 51-year-old patient with multiple and rare locations of Erdheim-Chester disease, particularly at the sphenoid sinus.


Subject(s)
Erdheim-Chester Disease/genetics , Mutation/genetics , Proto-Oncogene Proteins B-raf/genetics , Spinal Cord Compression/genetics , Erdheim-Chester Disease/diagnosis , Humans , Interferon-alpha/metabolism , Middle Aged , Sphenoid Sinus/surgery , Spinal Cord Compression/diagnosis
4.
Rev Med Interne ; 39(11): 875-878, 2018 Nov.
Article in French | MEDLINE | ID: mdl-30224098

ABSTRACT

INTRODUCTION: Epithelioid hemagioendothelioma (HHE) is a rare mesenchymal tumor of vascular origin and epithelial appearance, which develops like angiosarcoma to mimic endothelial cells. According to the literature, its prognosis is variable and remains unpredictable. CASE REPORT: We report a 72-year-old man who presented with an inflammatory pain in the left lower limb. Several osteolytic lesions involving the knee, the upper third of the tibia, the medial malleolus and the left calcaneus were identified. The diagnosis HHE was obtained by histological examination of a bone sample. The patient died after 5 months, despite taxol chemotherapy. CONCLUSION: No therapeutic behavior is standardized in this uncommon type of cancer.


Subject(s)
Bone Neoplasms/diagnosis , Hemangioendothelioma, Epithelioid/diagnosis , Aged , Bone Neoplasms/pathology , Hemangioendothelioma, Epithelioid/pathology , Humans , Male , Tomography, X-Ray
8.
Ann Dermatol Venereol ; 145(3): 173-177, 2018 Mar.
Article in French | MEDLINE | ID: mdl-29195664

ABSTRACT

BACKGROUND: Actinomycosis is a chronic and extensive granulomatous, bacterial infection. Revelation by oral ulceration is rare. PATIENTS AND METHODS: A 76-year-old patient with diabetes was treated with dabrafenib for stage IV melanoma. A follow-up visit revealed two ulcerated, infiltrated and hyperalgesic lesions of the palate and gingiva. There were no associated signs. The laboratory findings were normal. The possibility of squamous cell carcinoma occurring with BRAF inhibitors was discussed, despite the rarity of such cases in the literature. Histological examination showed an actinomycotic grain. A scan of the facial mass showed no osteitis. Antimicrobial therapy was initiated with amoxicillin for four months, with a favorable outcome. DISCUSSION: Actinomycetes are Gram-positive filamentous saprophytic bacteria of the oral cavity and the gastrointestinal tract. They can become pathogenic under the influence of several factors. Cervicofacial involvement in the form of a peri-mandibular inflammatory nodule with secondary fistulation on the skin or in the mouth is the classic presentation. To our knowledge, no cases of opportunistic infection under BRAF inhibitors have been described. Only two cases of tuberculosis have been reported with sorafenib. The initial presentation led to suspicion of squamous cell carcinoma. In our patient, poor oral hygiene and diabetes were the two key factors considered. Moreover, this is the first case reported under dabrafenib, which does not appear to be a favoring factor. We would stress the importance of mucosal examination in patients treated with BRAF inhibitors.


Subject(s)
Actinomycosis/drug therapy , Actinomycosis/microbiology , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Immunocompromised Host , Oral Ulcer/drug therapy , Oral Ulcer/microbiology , Actinomycosis/diagnosis , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Diabetes Mellitus, Type 2/complications , Female , Gingiva/pathology , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Melanoma/complications , Melanoma/drug therapy , Oral Ulcer/diagnosis , Oximes/administration & dosage , Oximes/adverse effects , Palate/pathology , Risk Factors , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Treatment Outcome
9.
J Gynecol Obstet Hum Reprod ; 46(4): 339-342, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28643661

ABSTRACT

OBJECTIVES: To study the influence of anaesthesia (local by cervical block vs. general or spinal anaesthesia) on height and volume of resection specimens in case of conization treatment for cervical intraepithelial neoplasia (CIN). METHODS: Prospective observational study of all patients who underwent a first treatment by loop electrosurgical excision procedure (LEEP) for CIN. Height of fresh resection specimens was first measured by the operator and then by the pathologist after formaldehyde fixation. Volume of fresh specimens was measured in a measuring cylinder by fluid displacement. RESULTS: One hundred patients were included and 35% of LEEP were performed under local anaesthesia. There was a significant difference in height of specimens depending on anaesthesia mode: after fixation, the average height was 11.2mm in the general or spinal anaesthesia group vs. 8.8mm in the local anaesthesia group (P=0.002). There was also a difference in terms of volume depending on anaesthesia mode: 1.6mL in local anaesthesia group vs. 2.3mm in general and spinal anaesthesia group (P=0.01). CONCLUSIONS: Anaesthesia mode has an impact on height and volume of LEEP specimens. In our experience, local anaesthesia could reduce LEEP specimen height.


Subject(s)
Anesthesia, Obstetrical/methods , Conization/methods , Electrosurgery/methods , Margins of Excision , Uterine Cervical Dysplasia/surgery , Uterine Cervical Neoplasms/surgery , Adult , Anesthesia, Obstetrical/adverse effects , Colposcopy/adverse effects , Colposcopy/methods , Conization/adverse effects , Electrosurgery/adverse effects , Female , Humans , Middle Aged , Neoplasm, Residual , Treatment Outcome , Uterine Cervical Neoplasms/pathology , Young Adult , Uterine Cervical Dysplasia/pathology
13.
Eur J Obstet Gynecol Reprod Biol ; 183: 52-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25461353

ABSTRACT

Transvaginal pelvic ultrasound is the first-line imaging examination for presumed benign ovarian tumors (PBOT) in adult women (Grade A). Ultrasound is sufficient for characterizing a unilocular anechoic cyst smaller than 7cm (Grade A). Magnetic resonance imaging is the recommended second-line investigation for indeterminate masses or masses larger than 7cm (Grade B). Serum CA-125 assay is not recommended for first-line diagnosis in adult women (Grade C). In women with a unilocular anechoic cyst, hormone therapy is ineffective and not recommended (Grade A). Ultrasound-guided aspiration is not recommended (Grade B). Abstention is an option in adult women with a unilocular asymptomatic anechoic cyst smaller than 10cm and no history of cancer (Grade B). If symptoms develop, laparoscopy is the gold standard for surgical treatment of PBOT (Grade A). Conservative surgical treatment (cystectomy) should be preferred to oophorectomy in pre-menopausal women without a previous history of cancer (Grade C). In cases of suspected adnexal torsion, laparoscopic surgical exploration is recommended (Grade B). Conservative treatment or detorsion without oophorectomy is recommended for pre-menopausal women regardless of the estimated torsion duration and macroscopic appearance of the ovary (Grade B). During pregnancy, expectant management is recommended for unilocular asymptomatic anechoic cysts smaller than 6cm (Grade C).


Subject(s)
Disease Management , Neoplasms/diagnosis , Neoplasms/therapy , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/therapy , Contraceptives, Oral, Hormonal/therapeutic use , Danazol/therapeutic use , Drug Therapy, Combination , Female , France , Humans , Laparoscopy , Magnetic Resonance Imaging , Ovariectomy , Progestins/therapeutic use , Ultrasonography
14.
Ann Oncol ; 25(2): 481-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24401926

ABSTRACT

BACKGROUND: Bone mineral density (BMD) loss is poorly defined in lymphoma patients. The aim of this study was to measure the extent of BMD loss in newly diagnosed lymphoma patients receiving chemotherapy. PATIENTS AND METHODS: This was a prospective, single-center study conducted in patients aged≥18 years with previously confirmed lymphoma treated by chemotherapy. Patients with low baseline BMD defined as Z/T-score less than or equal to -2.5 and/or history of osteoporotic fractures were excluded. BMD was measured at baseline before initiating chemotherapy and 1 year later. Predictive factors of BMD loss were investigated. RESULTS: Forty-one lymphoma patients (31 males and 10 females) receiving chemotherapy were enrolled. The median age at diagnosis was 59 (range: 19-86) years. Histological subtypes were predominantly diffuse large B-cell lymphoma (58%), mostly stage III-IV (54%). All patients received chemotherapy and 22% of patients received second-line treatment due to relapse or progressive disease. Thirty-two patients were evaluable at 1 year. The mean BMD changes were: -2.7%±3.9% for lumbar spine (P<0.001), -2.2%±7.6% for femoral neck (P<0.01) and -2.6%±4.5% for total hip (P<0.0001). In multivariate analysis, predictive factors of BMD loss at baseline were (i) at lumbar spine: female gender (P=0.01), higher lactate dehydrogenase level (P=0.04) and lower creatinine clearance (P=0.01); (ii) at total hip: lower albumin (P=0.01), higher corrected serum calcium (P<0.01), lower alkaline phosphatase (AP) (P<0.01) and autologous stem cell transplant (P=0.03); and (iii) at femoral neck: higher corrected serum calcium (P=0.02) and lower bone AP (P=0.01). CONCLUSION: Adult patients with known lymphoma receiving chemotherapy experienced significant BMD loss at 1 year.


Subject(s)
Antineoplastic Agents/therapeutic use , Bone Resorption/blood , Lymphoma/drug therapy , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Bone Density , Bone Resorption/pathology , Female , Femur Neck/pathology , Humans , Lumbar Vertebrae/pathology , Male , Middle Aged , Pilot Projects , Prospective Studies , Young Adult
15.
J Gynecol Obstet Biol Reprod (Paris) ; 42(8): 715-21, 2013 Dec.
Article in French | MEDLINE | ID: mdl-24200072

ABSTRACT

Most tumors of the ovary presumed benign according to clinical, biological and imaging data are cysts. A cyst is a newly formed cavity lined by epithelium. It tends to enlarge, and can undergo torsion, rupture and haemorrhage. Most prevalent cystic lesions, i.e. inclusion cysts, serous or mucinous cystadenomas, endometriotic cysts, mature teratoma and other cysts are described. Diagnostic methods of cytology and pathology are described and evaluated: intraoperative examination of cystic and peritoneal fluids are not recommended; intraoperative consultation can be performed on solid parts or implants, if the pathologist is familiar with these lesions, or if primary carcinoma is known. The value of intraoperative examination is good in benign and cancer cases, but unsatisfactory in borderline lesions, especially of mucinous type. Cryopreservation of ovarian tissue can be performed to preserve tumoral and normal tissue in Biobank for research protocol, or to maintain fertility through follicle preservation, in aseptic conditions. Transfer of samples towards the pathology laboratory can be performed either and preferably in fresh state, or in vacuum sealed bags at +4°C allowing a 2-day delay, or after immersion in a 15 × volume of 4% formalin. Cytological samples must be collected on citrate and sent immediately to the pathology laboratory, or fixed volume/volume in of absolute alcohol. The pathologist and the surgeon must collaborate to obtain good practice: intact labelled sample, accompanied by clinical information, transfer according to best local conditions, judicious use of intraoperative examination, knowing its possibilities and limitations, no excess delay of pathology report, even in difficult cases requiring expert opinion.


Subject(s)
Ovarian Cysts/pathology , Ovarian Neoplasms/pathology , Biological Specimen Banks/standards , Cryopreservation/methods , Cryopreservation/standards , Cystadenoma/pathology , Cytodiagnosis , Disease Progression , Female , Humans , Ovarian Cysts/classification , Ovarian Cysts/diagnosis , Ovarian Neoplasms/classification , Specimen Handling/methods , Specimen Handling/standards , Teratoma/pathology
16.
Eur J Cancer ; 49(17): 3694-707, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23910495

ABSTRACT

Oestrogen receptor negative (ER(-)) invasive ductal carcinoma (IDC) represents a significant clinical challenge and therefore prompts the discovery of novel biomarkers. Transient receptor potential melastatin 7 (TRPM7), a channel protein that also contains a regulatory kinase domain, is overexpressed in IDC and regulates migration. However, the molecular mechanism remains poorly defined. Here, we examined whether TRPM7 regulates migration by its channel function or by its kinase domain. A Magnesium Inhibited Cation current was recorded in two ER(-) highly metastatic breast cancer cell lines. Down-regulation of TRPM7 neither affected Ca(2+)-, nor Mg(2+)-homoeostasis but significantly reduced cell migration via a Ca(2+)-independent pathway. Notably, the overexpression of the truncated kinase domain form of TRPM7 decreased cell migration, while the overexpression of the wild-type form strongly increased it. Concomitantly, TRPM7 silencing reduced the myosin IIA heavy chain phosphorylation. Furthermore, we found higher TRPM7 expression in ER(-) IDC tissues and lymph nodes than in the non-invasive tumoural samples. In conclusion, TRPM7 plays a critical role in breast cancer cell migration through its kinase domain, and our data support the consideration of using TRPM7 as a novel biomarker and a potential therapeutic target in the treatment of human ER(-) IDC.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Movement/genetics , TRPM Cation Channels/physiology , Calcium/metabolism , Cell Movement/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , MCF-7 Cells , Neoplasm Metastasis , Phosphotransferases/chemistry , Phosphotransferases/physiology , Protein Structure, Tertiary/physiology , RNA, Small Interfering/pharmacology , Receptors, Estrogen/metabolism , TRPM Cation Channels/antagonists & inhibitors , TRPM Cation Channels/chemistry , Tumor Cells, Cultured
17.
Prog Urol ; 23(3): 195-202, 2013 Mar.
Article in French | MEDLINE | ID: mdl-23446284

ABSTRACT

PURPOSE: Prospective evaluation of bladder tumor targeting by Hexvix(®) fluorescence. PATIENTS AND METHODS: From September 2008 to April 2012, 107 patients have been evaluated using Hexvix(®) technique (blue light) for typically papillary bladder tumor or suspected bladder tumor. Clinical and pathological data have been collected prospectively and patients have been classified using EORTC score. RESULTS: From the 107 patients, 67 have been identified with bladder cancer and 328 samples have shown positive fluorescence in blue light. Compared to white light, 13 additional tumors have been diagnosed by Hexvix(®) for 11 patients: Cis (n=6), LMP (n=3), pTa low grade (n=3), pT1 low grade (n=1) (P=0.003). The false positive rate for Hexvix(®) was 53.4% versus 52% for white light. Previous TCC history, multifocality and EORTC score for recurrence and progression have been associated with better bladder cancer targeting by Hexvix(®) (P=0.007; P=0.01; P=0.03; P=0.04). CONCLUSION: In our experience, Hexvix(®) targeting was associated with better diagnosis for bladder cancer with 9% (13/144) of new positive samples (P=0.003). In our study, false positive rate is a critical point (53.4%). Multifocality, previous TCC, and EORTC score for recurrence and progression might allow selecting patients to be targeted by Hexvix(®).


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Cystoscopy/methods , Light , Photosensitizing Agents , Urinary Bladder Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Female , Fluorescence , France , Humans , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Survival Analysis , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder Neoplasms/mortality
18.
J Fr Ophtalmol ; 35(10): 786-91, 2012 Dec.
Article in French | MEDLINE | ID: mdl-23026701

ABSTRACT

Corneal dystrophies are relatively rare diseases of the young adult. We report a case of a Groenouw type II macular corneal dystrophy. A 34-year-old woman with no prior history was referred by her ophthalmologist for bilateral corneal dystrophy developing for several years. Physical examination revealed decreased visual acuity related to bilateral rounded corneal deposits. The patient underwent penetrating keratoplasty. The diagnosis of Groenouw type II macular corneal dystrophy was confirmed by pathological examination of the recipient cornea. The clinical, pathologic and therapeutic features are discussed.


Subject(s)
Corneal Dystrophies, Hereditary/diagnosis , Adult , Corneal Dystrophies, Hereditary/pathology , Diagnosis, Differential , Disease Progression , Female , Humans , Visual Acuity/physiology
19.
Stereotact Funct Neurosurg ; 90(4): 240-7, 2012.
Article in English | MEDLINE | ID: mdl-22699810

ABSTRACT

OBJECTIVE: Stereotactic biopsies are subject to sampling errors (essentially due to target selection). The presence of contrast enhancement is not a reliable marker of malignancy. The goal of the present study was to determine whether perfusion-weighted imaging can improve target selection in stereotactic biopsies. METHODS: We studied 21 consecutive stereotactic biopsies between June 2009 and March 2010. Perfusion-weighted magnetic resonance imaging (MRI) was integrated into our neuronavigator. Perfusion-weighted imaging was used as an adjunct to conventional MRI data for target determination. Conventional MRI alone was used to determine the trajectory. RESULTS: We found a linear correlation between regional cerebral blood volume (rCBV) and vessel density (number of vessels per mm(2); R = 0.64; p < 0.001). Perfusion-weighted imaging facilitated target determination in 11 cases (52.4%), all of which were histopathologically diagnosed as glial tumors. For glial tumors, which presented with contrast enhancement, perfusion-weighted imaging identified a more precisely delimited target in 9 cases, a different target in 1 case, and exactly the same target in 1 other case. In all cases, perfusion-selected sampling provided information on cellular features and tumor grading. rCBV was significantly associated with grading (p < 0.01), endothelial proliferation (p < 0.01), and vessel density (p < 0.01). For lesions with rCBV values ≤1, perfusion-weighted MRI did not help to determine the target but was useful for surgical management. CONCLUSIONS: For stereotactic biopsies, targeting based on perfusion-weighted imaging is a feasible method for reducing the sampling error and improving target selection in the histopathological diagnosis of tumors with high rCBVs.


Subject(s)
Brain Neoplasms/pathology , Glioma/pathology , Lymphoma/pathology , Magnetic Resonance Angiography/methods , Stereotaxic Techniques , Biopsy/methods , Brain/pathology , Brain/surgery , Brain Neoplasms/surgery , Female , Glioma/surgery , Humans , Lymphoma/surgery , Male , Middle Aged
20.
Rev Mal Respir ; 29(1): 70-3, 2012 Jan.
Article in French | MEDLINE | ID: mdl-22240223

ABSTRACT

INTRODUCTION: Scwhannomas are uncommon neurogenic tumors of the mediastinum. Most of them are located in the posterior mediastinum usually in the paralateral gutters. We report the case of an uncommon localisation of such a tumour appended to the right vagus nerve in the middle mediastinum. CASE REPORT: The patient was 50 years old and complained of thoracic pain, shortness of breath and dysphagia. CT scanning of thorax and abdomen revealed a heterogeneous mass in the middle mediastinum, which was not visible on plain radiography. Further investigation included transoesophageal ultrasound and PET scan. The diagnosis was confirmed by histopathology after mini video-assisted thoracotomy. The schwannoma was entirely removed without any post-surgical complications. CONCLUSION: We report a novel case of schwannoma arising from the vagus nerve and review the diagnostic strategies. PET scanning has poor sensitivity and specificity and does not therefore contribute to confirm the diagnosis which depends on exploring the mediastimun surgically.


Subject(s)
Cranial Nerve Neoplasms/diagnosis , Cranial Nerve Neoplasms/therapy , Neurilemmoma/diagnosis , Neurilemmoma/therapy , Vagus Nerve Diseases/diagnosis , Vagus Nerve Diseases/therapy , Vagus Nerve , Cranial Nerve Neoplasms/pathology , Diagnostic Techniques, Surgical , Humans , Incidental Findings , Male , Middle Aged , Neurilemmoma/pathology , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/diagnostic imaging , Pancreatitis, Chronic/surgery , Radiography, Thoracic , Vagus Nerve/pathology , Vagus Nerve Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...